Geoffrey L. Uy, MD - Washington ...

Dr. Geoffrey L. Uy

Claim this profile

Washington University School of Medicine

Expert in Acute Myelogenous Leukemia
Expert in Acute Myeloid Leukemia
28 reported clinical trials
63 drugs studied

About Geoffrey L. Uy

Education:

  • Earned an MD from Washington University School of Medicine.

Experience:

  • Over 21 years of clinical experience as an oncologist.
  • Specializes in Oncology, with a subspecialty in Hematologic Oncology.
  • Affiliated with Barnes-Jewish Hospital and Siteman Cancer Center.
  • Recognized for exceptional patient care and high satisfaction ratings.

Area of expertise

1Acute Myelogenous Leukemia
Global Leader
Geoffrey L. Uy has run 15 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
FLT3 negative
FLT3 positive
CD7 positive
2Acute Myeloid Leukemia
Global Leader
Geoffrey L. Uy has run 13 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
FLT3 negative
FLT3 positive
CD7 positive

Affiliated Hospitals

Image of trial facility.
Washington University School Of Medicine
Image of trial facility.
Siteman Cancer Center At West County Hospital

Clinical Trials Geoffrey L. Uy is currently running

Image of trial facility.

Dendritic Cells

for Graft-versus-Host Disease

Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells. To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.
Recruiting1 award N/A3 criteria
Image of trial facility.

Blinatumomab + Chemotherapy

for Leukemia

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria

More about Geoffrey L. Uy

Clinical Trial Related2 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Geoffrey L. Uy has experience with
  • Cytarabine
  • Cyclophosphamide
  • Dexamethasone
  • Uproleselan
  • Cytokine Induced Memory-like NK Cell Adoptive Therapy
  • Isatuximab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Geoffrey L. Uy specialize in?
Is Geoffrey L. Uy currently recruiting for clinical trials?
Are there any treatments that Geoffrey L. Uy has studied deeply?
What is the best way to schedule an appointment with Geoffrey L. Uy?
What is the office address of Geoffrey L. Uy?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security